Drugs / Autologous Genetically modified T cells
Autologous Genetically modified T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01352286 | May 2011 → Aug 2017 | plasma cell myeloma | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Genetically modified T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01352286 ↗ |
| Modality | Cell therapy | “autologous genetically modified T cells transduced to express the high affinity NY-ESO-1c259 TCR” NCT01352286 ↗ |